SAN MARCOS, Texas, Nov. 3 Texas State University and Orizon Research Institute announced the signing of an agreement today that will permit University Researchers to continue efforts through in vivo testing to further determine the potential and effectiveness of ALKA-V6, a compound which has shown remarkable ability to kill cancer cells and inhibit the HIV virus in laboratory experiments.
The research will evaluate the effects of ALKA-V6 on animal organisms, and will be highly replicated with the goal of moving knowledge about the compound toward eventual FDA approval.
Dr. Troy Chesnut, Managing Member of Orizon Research Institute, stated, "We are excited to move our research from artificial laboratory systems to animal organisms. These next 18 months of research should confirm previous studies and provide more answers about this promising product."
The prelude from the Texas State University research proposal addresses the reasons for optimism about the product. "ALKA-V6 is a modified value-added silicon compound......This product has been imputed to have several health benefits including anti-microbial activity, bone remodeling and joint health promoting functions as well as chemotherapeutic benefits against cancer and viral infections....In response to numerous testimonials/case studies, empirical evidence and written personal and contractual statements about the putative cancer reducing and alleviation in symptoms associated with several viral diseases, we previously evaluated the anticancer and anti-HIV effects in in vitro models. Our results largely corroborated the empirical observations and many in vitro model systems. ALKA-V6 proved highly effective in mitigating causative factors and conditions that promote cancer and HIV infections. ALKA-V6 was extremely effective in preventing sodium azide induced mutations, cancer cell survival, and cancer cell adhesion. In addition, at very low concentrations, ALKA-V6 was also very effective in promoting apoptosis, preventing free radical mediated DNA damage, activating free radical neutralizing systems such as glutathione, superoxide dismutase and catalase. ALKA-V6 was also very effective in its antiviral activities, and at very low doses it was highly effective in inhibiting viral transcription and replication. In addition, it was also very effective in reducing viral cell attachment and ability of the virus to evade the immune system.
In spite of these scientifically proven effects, most of these studies have been conducted in in vitro systems.....
...Systematic studies need to be conducted in in vivo systems to decipher the genetic and physiological mechanism of action, determine the effective dosages for health promoting activity.....End point measurements as related to modulation of genetic and metabolic pathways relevant to anti-metastatic and anti-retroviral effects are imperative to completely establish the functionality of ALKA-V6 in promoting homeostasis....
The results from this phase of testing may also result in scientific acceptance of the product as an effective alternative/complementary tool for management and prevention of different diseases."
Orizon Research Institute of Odessa, Texas is the international distributor of ALKA V-6. Orizon remains committed to providing the ALKA-V6 compound to the general public as an affordably priced nutritional supplement that can be purchased directly from the company web site. The phase 1 ALKA-V6 research study conducted at Texas State is also available on the Orizon Research web site at www.orizonresearch.com.
CONTACT: Orizon Research, LLC, 1-877-367-7770, email@example.com
SOURCE Orizon Research Institute